WO1995003798A3 - UTILISATION D'AGONISTES D'α-2 A EFFICACITE CENTRALE POUR INHIBER LE METABOLISME DE POSTAGRESSION - Google Patents

UTILISATION D'AGONISTES D'α-2 A EFFICACITE CENTRALE POUR INHIBER LE METABOLISME DE POSTAGRESSION Download PDF

Info

Publication number
WO1995003798A3
WO1995003798A3 PCT/EP1994/002475 EP9402475W WO9503798A3 WO 1995003798 A3 WO1995003798 A3 WO 1995003798A3 EP 9402475 W EP9402475 W EP 9402475W WO 9503798 A3 WO9503798 A3 WO 9503798A3
Authority
WO
WIPO (PCT)
Prior art keywords
postaggression
agonists
metabolism
inhibiting
centrally effective
Prior art date
Application number
PCT/EP1994/002475
Other languages
German (de)
English (en)
Other versions
WO1995003798A2 (fr
Inventor
Norbert Mertes
Christiane Goeters
Joseph Zander
Martin Kuhmann
Hans-Michael Brecht
Original Assignee
Boehringer Ingelheim Int
Boehringer Ingelheim Kg
Norbert Mertes
Christiane Goeters
Joseph Zander
Martin Kuhmann
Brecht Hans Michael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int, Boehringer Ingelheim Kg, Norbert Mertes, Christiane Goeters, Joseph Zander, Martin Kuhmann, Brecht Hans Michael filed Critical Boehringer Ingelheim Int
Priority to AU75331/94A priority Critical patent/AU7533194A/en
Priority to EP94925399A priority patent/EP0719139A1/fr
Publication of WO1995003798A2 publication Critical patent/WO1995003798A2/fr
Publication of WO1995003798A3 publication Critical patent/WO1995003798A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'agonistes des récepteurs α-2 dans le traitement du syndrome de postagression.
PCT/EP1994/002475 1993-07-29 1994-07-27 UTILISATION D'AGONISTES D'α-2 A EFFICACITE CENTRALE POUR INHIBER LE METABOLISME DE POSTAGRESSION WO1995003798A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU75331/94A AU7533194A (en) 1993-07-29 1994-07-27 Use of centrally effective alpha-2 agonists for inhibiting postaggression metabolism
EP94925399A EP0719139A1 (fr) 1993-07-29 1994-07-27 UTILISATION D'AGONISTES D'$g(a)-2 A EFFICACITE CENTRALE POUR INHIBER LE METABOLISME DE POSTAGRESSION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4325491.8 1993-07-29
DE19934325491 DE4325491A1 (de) 1993-07-29 1993-07-29 Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels

Publications (2)

Publication Number Publication Date
WO1995003798A2 WO1995003798A2 (fr) 1995-02-09
WO1995003798A3 true WO1995003798A3 (fr) 2001-05-03

Family

ID=6494011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/002475 WO1995003798A2 (fr) 1993-07-29 1994-07-27 UTILISATION D'AGONISTES D'α-2 A EFFICACITE CENTRALE POUR INHIBER LE METABOLISME DE POSTAGRESSION

Country Status (4)

Country Link
EP (1) EP0719139A1 (fr)
AU (1) AU7533194A (fr)
DE (1) DE4325491A1 (fr)
WO (1) WO1995003798A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU704972B2 (en) 1994-08-04 1999-05-13 H. Lundbeck A/S Novel benzimidazole derivatives
EP0812197A2 (fr) * 1995-02-28 1997-12-17 Beiersdorf-Lilly GmbH Utilisation de la moxonidine pour le traitement de l'atherosclerose
BR9709546A (pt) * 1996-06-06 1999-08-10 Lilly Co Eli Formulação e método para tratamento de insuficiéncia cardíaca digestiva
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
AUPP020297A0 (en) * 1997-11-05 1997-11-27 University Of Melbourne, The A novel receptor, and compounds which bind thereto
DE19938825A1 (de) * 1999-08-19 2001-04-26 Boehringer Ingelheim Pharma Wirkstoffkombination mit Clonidin
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004040A1 (fr) * 1990-09-10 1992-03-19 Applied Research Systems Ars Holding N.V. Traitement de l'obesite a l'aide d'un agoniste alpha-2-adrenergique et d'un peptide liberateur de somatotrophines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004040A1 (fr) * 1990-09-10 1992-03-19 Applied Research Systems Ars Holding N.V. Traitement de l'obesite a l'aide d'un agoniste alpha-2-adrenergique et d'un peptide liberateur de somatotrophines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLEMMONS, D.R. ET AL: "ROLE OF INSULIN-LIKE GROWTH FACTORS AND GROWTH HORMONE IN REVERSING CATABOLIC STATES", HORMONAL RESEARCH, vol. 38, no. 2, 1992, pages 37 - 40 *
DATABASE WPI Week 9214, Derwent World Patents Index; AN 92-114064 *
FLEMING, R.Y. ET AL: "EFFECT OF RECOMBINANT HUMAN GROWTH HORMONE ON CATABOLIC HORMONES AND FREE FATTY ACIDS FOLLOWING THERMAL INJURY", THE JOURNAL OF TRAUMA, vol. 32, no. 6, 1992, pages 698 - 702 *
JEEVANANDAM, M. ET AL: "DECREASED GROWTH HORMONE LEVELS IN THE CATABOLIC PHASE OF SEVERE INJURY", SURGERY, vol. 111, no. 5, 1992, pages 495 - 502 *
JURCOVICOVA, J. ET AL: "THE PARADOX OF ALPHA2 ADRENERGIC REGULATION OF PROLACTIN (PRL) SECRETION. I. THE PRL-RELEASING ACTION OF THE ALPHA2 RECEPTOR AGONISTS", BRAIN RESEARCH BULLETIN, vol. 23, no. 6, 1989, pages 417 - 424 *
KOEA, J.B. ET AL: "GROWTH HORMONE THERAPY INITIATED BEFORE STARVATION AMELIORATES CATABOLIC STATE AND ENHANCES THE PROTEIN-SPARING EFFECT OF TOTAL PARENTERAL NUTRITION", BRITISH JOURNAL OF SURGERY, vol. 80, no. 6, June 1993 (1993-06-01), pages 740 - 744 *

Also Published As

Publication number Publication date
AU7533194A (en) 1995-02-28
EP0719139A1 (fr) 1996-07-03
DE4325491A1 (de) 1995-02-02
WO1995003798A2 (fr) 1995-02-09

Similar Documents

Publication Publication Date Title
ZA981132B (en) Methods, compositions and articles for reducing or preventing the effects of inflammation.
EP0717592A4 (fr) Procede et composition de traitement du syndrome d'apathie-amotivation
DE69626513D1 (en) Imidazolverbindungen
AU2067892A (en) Corrosion inhibitors
AU1510292A (en) Milky detergent composition for hard surfaces
AU1880588A (en) Corrosion inhibiting compositions
NO871091D0 (no) Komposittanordning for katodisk beskyttelse av substrater i kontakt med denne, og anvendelse av anordningen.
EP0614367A4 (en) Substituted lactose and lactosamine derivatives as cell adhesion inhibitors.
AU5852794A (en) Sterilization devices, sporidical compositions, sterilization methods, and devices for reducing surface tension
AU1933592A (en) Corrosion inhibitors
AU7558594A (en) Coke and corrosion retardation process and composition
MXPA94006948A (es) Epibatidina y derivados de la misma como agonistasy antagonistas del receptor colinergico.
AU4396993A (en) Dipeptidyl peptidase-I, cloning it, and therapeutic agents containing inhibitors thereof
AU555628B2 (en) Multifunctional cloning vectors for use in streptomyces, bacillus and e-coli
WO1995003798A3 (fr) UTILISATION D'AGONISTES D'α-2 A EFFICACITE CENTRALE POUR INHIBER LE METABOLISME DE POSTAGRESSION
GR3034757T3 (en) Compositons for the treatment of chronic fatigue syndrome.
HUT70069A (en) Detergent composition containing block copolymer, and using the block copolymer for binding of metals
AU4246289A (en) Substituted 1,3,5-triazinetriones, processes for their preparation and their use against parasitic protozoa
PH30815A (en) Composition.
AU7562594A (en) Sequence-specific glycoconjugate transcriptional antagonists
EP0629689A3 (en) Grease composition.
AU4100793A (en) Homology cloning
EP0444605A3 (en) Angiotensin converting enzyme inhibitor, method for preparing it, composition containing the same and use thereof
AU7079887A (en) N, s containing corrosion inhibitors
HUT70614A (en) 3,4-dioxo-1-cyclobuten-1-yl-substituted (indolyl-alkyl)-pyridine- and -pyrimidine derivatives and antimigraine compositions containing them as active component

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG BR BY CA CH CN CZ FI HU JP KR KZ LV NO NZ PL RO RU SK UA US UZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994925399

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1994925399

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG BR BY CA CH CN CZ FI HU JP KR KZ LV NO NZ PL RO RU SK UA US UZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWR Wipo information: refused in national office

Ref document number: 1994925399

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994925399

Country of ref document: EP